Multaq(dronedarone)
Dronedarone, Multaq (dronedarone) is a small molecule pharmaceutical. Dronedarone was first approved as Multaq on 2009-07-01. It is used to treat atrial fibrillation and cardiac arrhythmias in the USA. It has been approved in Europe to treat atrial fibrillation. It is known to target potassium voltage-gated channel subfamily A member 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Dronedarone, Multaq
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| multaq | New Drug Application | 2026-01-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
| cardiac arrhythmias | EFO_0004269 | D001145 | I49.9 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 4 | 12 | 13 | 17 | 45 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | 1 | 2 | 3 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | — | 1 |
| Thromboembolism | D013923 | — | — | — | — | — | 1 | — | 1 |
| Heart murmurs | D006337 | — | R01.0 | — | — | — | 1 | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Recurrence | D012008 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 2 | 3 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | 3 | — | — | 3 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sick sinus syndrome | D012804 | EFO_0004275 | I49.5 | — | — | — | — | 1 | 1 |
| Shock | D012769 | — | R57.1 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Tricuspid valve insufficiency | D014262 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dronedarone |
| INN | dronedarone |
| Description | Dronedarone is a member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias. It has a role as an anti-arrhythmia drug, an environmental contaminant and a xenobiotic. It is a member of 1-benzofurans, a tertiary amino compound, a sulfonamide, an aromatic ketone and an aromatic ether. |
| Classification | Small molecule |
| Drug class | antiarrhythmics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 141626-36-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL184412 |
| ChEBI ID | 50659 |
| PubChem CID | 208898 |
| DrugBank | DB04855 |
| UNII ID | JQZ1L091Y2 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNA5
KCNA5
Organism
Homo sapiens
Gene name
KCNA5
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily A member 5
Protein synonyms
cardiac potassium channel, HPCN1, insulinoma and islet potassium channel, potassium channel 1, potassium channel, voltage gated shaker related subfamily A, member 5, potassium voltage-gated channel, shaker-related subfamily, member 5, Voltage-gated potassium channel HK2, voltage-gated potassium channel protein Kv1.5, Voltage-gated potassium channel subunit Kv1.5
Uniprot ID
Mouse ortholog
Kcna5 (16493)
potassium voltage-gated channel subfamily A member 5 (Q9Z1R6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Multaq – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dronedarone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,271 documents
View more details
Safety
Black-box Warning
Black-box warning for: Multaq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,072 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use